| Paraquat-A deadly poison: Report of a case and review K Saravu, S Sekhar, A Pai, AS Barkur, V Rajesh, JR Earla Indian journal of critical care medicine: peer-reviewed, official …, 2013 | 53 | 2013 |
| Clinical pharmacists: The major support to Indian healthcare system in near future NPS Deshpande PR, Vantipalli R, Chaitanya Lakshmi C H, Rao E J, Regmi B, Ahad A J Pharm Bioall Sci, 161-74, 2015 | 50 | 2015 |
| Pharm D: A new concept in India PR Deshpande, KKA Farooq, DM John, EJ Rao Journal of Pharmacy & Bioallied Sciences 4 (1), 84, 2012 | 24 | 2012 |
| How useful are digital health terms for outcomes research? An ISPOR special interest group report A Burrell, Z Zrubka, A Champion, V Zah, L Vinuesa, AP Holtorf, ... Value in Health 25 (9), 1469-1479, 2022 | 19 | 2022 |
| Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis JR Earla, GJ Hutton, JD Thornton, H Chen, ML Johnson, RR Aparasu Patient preference and adherence 14, 2187, 2020 | 14 | 2020 |
| Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data JR Earla, R Paranjpe, N Kachru, GJ Hutton, RR Aparasu Research in Social and Administrative Pharmacy, 2020 | 12 | 2020 |
| Factors associated with prescribing oral disease modifying agents in multiple sclerosis: a real-world analysis of electronic medical records JR Earla, GJ Hutton, JD Thornton, RR Aparasu Multiple Sclerosis and Related Disorders 45, 102334, 2020 | 10 | 2020 |
| Marginal health care expenditure burden among US civilian noninstitutionalized individuals with multiple sclerosis: 2010-2015 JR Earla, JD Thornton, GJ Hutton, RR Aparasu Journal of Managed Care & Specialty Pharmacy 26 (6), 741-749, 2020 | 10 | 2020 |
| The PICOTS-ComTeC Framework for Defining Digital Health Interventions: An ISPOR Special Interest Group Report Z Zrubka, A Champion, AP Holtorf, R Di Bidino, JR Earla, AT Boltyenkov, ... Value in Health 27 (4), 383-396, 2024 | 4 | 2024 |
| Prescribing of disease modifying agents in older adults with multiple sclerosis A Talwar, JR Earla, GJ Hutton, RR Aparasu Multiple Sclerosis and Related Disorders 57, 103308, 2022 | 4 | 2022 |
| Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials L Fan, Y Zhang, P Maguire, D Muston, M Monberg, JR Earla, A Mihai, ... Journal of market access & health policy 10 (1), 2078474, 2022 | 3 | 2022 |
| Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries RR Aparasu, S Sura, JR Earla, A Shiozawa, DB Ng, CR Schermer Advances in Therapy 37, 3584-3605, 2020 | 3 | 2020 |
| Real world treatment patterns and survival by germline BRCA (gBRCA) mutation status in patients with HER2-negative early breast cancer (eBC) in the US community oncology … JC Andersen, JR Earla, N Fulcher, J Ndukum, NJ Robert, ME Robson, ... Journal of Clinical Oncology 41 (16_suppl), e12535-e12535, 2023 | 2 | 2023 |
| Comparative treatment effectiveness of oral fingolimod and conventional injectable disease‐modifying agents in multiple sclerosis JR Earla, GJ Hutton, DJ Thornton, H Chen, ML Johnson, RR Aparasu Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41 (5 …, 2021 | 2 | 2021 |
| Health care resource utilization and economic burden in multiple sclerosis patients JR Earla, JD Thornton, RR Aparasu Research in Social and Administrative Pharmacy 14 (6), e19, 2018 | 2 | 2018 |
| Economic Aspects, Economic Assessment and Career Preferences of Doctor of Pharmacy (PharmD) Students in India PAP Deshpande PR, Bhusare K, Chandrakar VR, Rao EJ, Raut A, Pawar S, Sajith ... Indian Journal of Pharmaceutical Education and Research 52 (2), 181-96, 2018 | 2 | 2018 |
| Comparative adherence trajectories of oral disease‐modifying agents in multiple sclerosis JR Earla, J Li, GJ Hutton, ML Johnson, RR Aparasu Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 43 (6 …, 2023 | 1 | 2023 |
| Factors associated with switching from injectable to oral disease modifying agents among patients with multiple sclerosis J Li, SG Chikermane, JR Earla, GJ Hutton, RR Aparasu Multiple Sclerosis and Related Disorders 60, 103703, 2022 | 1 | 2022 |
| Association of the Healthcare Effectiveness Data and Information Set (HEDIS) Follow-Up Care Measures and Medication Adherence Among Medicaid Insured Children with ADHD JR Earla, S Abughosh, H Chen Journal of Attention Disorders 26 (3), 370-376, 2022 | 1 | 2022 |
| Factors associated with oral fingolimod use over injectable disease-modifying agent use in multiple sclerosis JR Earla, GJ Hutton, JD Thornton, H Chen, ML Johnson, RR Aparasu Exploratory Research in Clinical and Social Pharmacy 2, 100021, 2021 | 1 | 2021 |
Rajender R. Aparasu, PhD, FAPhADepartment of Pharmaceutical Health Outcomes and Policy - University of Houston College of Pharmacy在 uh.edu 的电子邮件经过验证
